Ranbaxy shares slide 35% on US import alert

Ranbaxy office Ranbaxy is India's biggest drugmaker

Related Stories

Shares in India's biggest drugmaker, Ranbaxy, have sunk to a record low after the US drugs regulator issued an import alert for one of its plants.

The alert by the US Food and Drug Administration (FDA) allows authorities to detain drugs on the list "without physical sampling and analysis".

The FDA says it issues an alert when a firm does not conform with "current good manufacturing practices".

Ranbaxy shares fell as much as 35% to their lowest since its listing in 1991.

The FDA issued an alert for products made at Ranbaxy's Mohali plant on Friday.

This comes months after Ranbaxy agreed to pay a record $500m (£313m) in fines over drug safety charges in the US.

HSBC downgraded the firm to "underweight" from "overweight" over the import alert, indicating it was less optimistic about the company's prospects.

Ranbaxy has faced problems in the US over the past several years, including delays in getting approval from the FDA for its drugs because of quality control problems at some of its Indian manufacturing facilities.

More on This Story

Related Stories

The BBC is not responsible for the content of external Internet sites

More Business stories



Try our new site and tell us what you think. Learn more
Take me there

Copyright © 2015 BBC. The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.